Glucagon-Like Peptide 1 Concept

subject area of

• 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial  Journal Articles
• A novel self-assembling peptide nanofiber hydrogel with glucagon-like peptide-1 functionality enhances islet survival to improve islet transplantation outcome in diabetes treatment.  Journal Articles
• Adverse metabolic effects of a hypercaloric, high-fat diet in rodents precede observable changes in body weight  Journal Articles
• Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial  Journal Articles
• Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis  Journal Articles
• Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data  Journal Articles
• Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human  Journal Articles
• Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid.  Journal Articles
• Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis  Journal Articles
• GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R  Journal Articles
• Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis  Journal Articles
• Glucagon-Like Peptide-1 and Blood Pressure in Young and Healthy Adults from the General Population  Journal Articles
• Glucagon-Like Peptide-1 as Predictor of Body Mass Index and Dentate Gyrus Neurogenesis: Neuroplasticity and the Metabolic Milieu  Journal Articles
• Healthy lifestyle and glucagon-like peptide-1 in young and healthy adults: A population-based study  Journal Articles
• Immunometabolism Sentinels: Gut Surface T-Cells Regulate GLP-1 Availability  Journal Articles
• Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis  Journal Articles
• Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis  Journal Articles
• Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis  Journal Articles
• Local, exendin-(9—39)-insensitive, site of action of GLP-1 in canine ileum  Journal Articles
• Metabolic endotoxemia is dictated by the type of lipopolysaccharide  Journal Articles
• Metabolic, stress, and inflammatory biomarker responses to glucose administration in Fischer-344 rats: intraperitoneal vs. oral delivery  Journal Articles
• Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD  Journal Articles
• Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD  Journal Articles
• Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo  Journal Articles
• Relationships of iron metabolism with insulin resistance and glucose levels in young and healthy adults  Journal Articles
• Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome  Journal Articles
• Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions  Journal Articles